652 related articles for article (PubMed ID: 9280685)
1. [Pharmacological therapy of complicated Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
[TBL] [Abstract][Full Text] [Related]
3. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
4. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
5. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
6. Effective strategies in the management of Parkinson's disease.
Wills AJ
Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
[TBL] [Abstract][Full Text] [Related]
7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
8. Ropinirole as compared with levodopa in Parkinson's disease.
Hiner BC; Earnhart M
N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
[No Abstract] [Full Text] [Related]
9. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
10. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Verhagen Metman L
Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
[TBL] [Abstract][Full Text] [Related]
11. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
12. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
13. Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC; Vassallo M; Ross IN
Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
[No Abstract] [Full Text] [Related]
14. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Olanow CW; Jankovic J
Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111
[TBL] [Abstract][Full Text] [Related]
16. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
[No Abstract] [Full Text] [Related]
17. [Early treatment of Parkinson's disease with levodopa].
Odekerken VJ; Post B; Verschuur CV; de Bie RM
Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
[TBL] [Abstract][Full Text] [Related]
18. [Physiopathology of the dyskinesias induced by L-dopa].
Grandas F; López-Ariztegui N
Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
[TBL] [Abstract][Full Text] [Related]
19. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
20. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
